SteadyMed Submits Type A Meeting Request Package to FDA
28. September 2017 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Sept. 28, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Receives Refusal to File Letter from FDA for Trevyent® New Drug Application
31. August 2017 06:45 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate Update
11. August 2017 08:30 ET
|
SteadyMed Therapeutics
Submitted New Drug Application for Trevyent for the Treatment of Pulmonary Arterial Hypertension On track for Mid-2018 U.S. Commercial Launch, Subject to FDA Approval SAN RAMON, Calif., Aug. 11,...
SteadyMed to Present at the 2017 Wedbush PacGrow Healthcare Conference
09. August 2017 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical Affairs
31. Juli 2017 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Submits New Drug Application for Trevyent®
30. Juni 2017 14:35 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 30, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed to Present at the 2017 JMP Securities Life Sciences Conference
13. Juni 2017 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 13, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Raises Additional Capital from Key Institutional Shareholder
26. Mai 2017 08:42 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 26, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update
12. Mai 2017 08:30 ET
|
SteadyMed Therapeutics
Raised $28.2 Million in Net Proceeds in a Private PlacementReceived a Favorable IPR Ruling Invalidating United Therapeutics’ ‘393 PatentCompleted a Clinical Validation Study for Trevyent®On Track to...
SteadyMed Receives USPTO Notice of Allowance for Patent Related to Key PatchPump® Technology
02. Mai 2017 08:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...